Overview
KURA market data
Price History
KURA price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$3.18 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.41 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -411.2% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $5.52 – $12.49 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $854M · P/B 5.19 · P/S 11.92.
Company News
Accelerant Holdings, CorMedix, Birkenstock And Other Big Stocks Moving Higher On ThursdayBenzinga · Aug 13, 2026, 1:57 PM
Kura Oncology shares are trading higher after the company reported better-than-expected Q2 EPS results. Also, Wedbush maintained an Outperform rating on the stock and raised its price target from $36 to $38.Benzinga · Aug 13, 2026, 1:03 PM
Wedbush Maintains Outperform on Kura Oncology, Raises Price Target to $38Benzinga · Aug 13, 2026, 12:57 PM
8-K filing — Kura Oncology, Inc. (KURA)SEC EDGAR · Aug 12, 2026, 8:10 PM
Kura Oncology Q2 EPS $(0.77) Beats $(0.87) Estimate, Sales $20.874M Miss $21.420M EstimateBenzinga · Aug 12, 2026, 8:03 PM
Kura Oncology Announces Publication Of Manuscript In Blood, Journal Of The American Society Of Hematology, Detailing Discovery And Preclinical Development Of ZiftomenibBenzinga · Aug 10, 2026, 12:36 PM
Kura Oncology to Report Second Quarter Financial ResultsGlobenewswire Inc · Aug 5, 2026, 12:15 PM
Wedbush Reiterates Outperform on Kura Oncology, Maintains $36 Price TargetBenzinga · Jul 28, 2026, 12:55 PM
Kura Oncology Announces Updated Phase 1A Results From Ongoing FIT-001 Clinical Trial; Data Demonstrate Encouraging And Durable Clinical Activity Of Darlifarnib Plus Cabozantinib In Cabozantinib-Naïve Patients With Advanced Clear Cell Renal Cell CarcinomaBenzinga · Jul 27, 2026, 10:34 AM
Kura Oncology To Feature Updated Phase 1a Results From Ongoing FIT-001 Phase 1a/1b Clinical Trial Evaluating Darlifarnib In Combination With Cabozantinib In Advanced Renal Cell Carcinoma In Oral Presentation At 2026 KCRSBenzinga · Jul 14, 2026, 11:21 AM